Plasma renin activity (PRA) has been shown to predict future cardiovascular (CV) events in observational studies and in clinical trials and to be associated with the prevalence of chronic renal disease in hypertensive subjects. In a nested case -control study, we explored the relationship between CV and renal outcomes and all-cause mortality with baseline measurements of PRA among hypertensive adults randomized in the ASCOT trial.
Introduction
The renin -angiotensin-aldosterone system (RAAS) plays an important role in circulatory haemodynamics through its effects on vascular tone and salt and water homeostasis. 1 In addition, there is increasing evidence that activation of the RAAS at a tissue level plays a pathophysiological role in cardiac and vascular hypertrophy, glomerular sclerosis, and atherosclerosis. 2, 3 The activity of the RAAS may be inhibited by several AHT drugs which, in addition to their blood pressure-lowering properties, may confer target-organ protection. 1 For more than 30 years, there has been much interest and controversy over the use of the measurement of plasma renin activity (PRA) as a biomarker for the prediction of future cardiovascular (CV) events. The earliest report of Brunner et al. 4 in 1972 in a small study of subjects with essential hypertension appeared to demonstrate that subjects with low levels of PRA had a significantly lower incidence of myocardial infarction (MI) and stroke during 10 years of observation compared with those subjects with normal or high levels of PRA. Subsequently, these authors proposed that PRA was a risk factor in patients with essential hypertension and important not only for the prediction of future CV events but also for the determination of treatment modalities. Following early reports, a number of observational studies in unselected subjects and in differing patient groups have provided conflicting evidence as to whether measurements of PRA do or do not reliably and reproducibly predict future CV events. 5 -8 More recently, in the context of clinical trials in patients with coronary heart disease (CHD) and in patients with heart failure, there have been reports that PRA levels predict CV and all-cause mortality. 9 -11 In addition, there are now reports that PRA may be a predictor of renal outcomes in patients with CHD. 12 In the present study, we report findings from a nested case-control study, conducted in patients recruited to the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), to ascertain the role of PRA as a potential biomarker for predicting CV and renal outcomes and all-cause mortality in treated hypertensive patients during a follow-up period of 5.5 years.
Methods
A case -control study nested in the blood pressure-lowering arm (BPLA) of the ASCOT trial 13, 14 was used to determine the association between baseline PRA with subsequent events. For the purpose of these analyses, those with any history of CV disease at the baseline were excluded.
Patients and recruitment
The detailed ASCOT protocol has been published previously 13 and further information is available at http://www.ascotstudy.org. Hypertensive patients aged 40 -79 years, with three or more other risk factors for CV disease but no history of prior MI, current CHD including heart failure, or currently treated angina were eligible. In ASCOT-BPLA, 9098 patients were randomized from the UK and Ireland, to either amlodipine adding perindopril as required (amlodipine-based) or atenolol adding bendroflumethiazide as required (atenolol-based). At each follow-up visit, AHT drug therapy was titrated and additional drugs added to achieve target blood pressure levels of ,140/90 mmHg for non-diabetic patients and ,130/80 mmHg for diabetic patients.
In addition to randomization into ASCOT-BPLA, those with a fasting total cholesterol of ,6.5 mmol/L (250 mg/dL) were further randomized, using a factorial design, to either 10 mg atorvastatin daily or matching placebo in the lipid-lowering arm of the trial (ASCOT-LLA). 15 The endpoints for the purpose of the present case-control analysis were the first event of a composite CV endpoint (which included symptomatic non-fatal MI, fatal CHD, coronary revascularization, fatal and non-fatal stroke, and development of heart failure), total CHD events (symptomatic non-fatal MI, fatal CHD, and coronary revascularization), deterioration in renal function (50% increase in serum creatinine), and all-cause mortality.
ASCOT-LLA was stopped prematurely after a median follow-up of 3.3 years owing to highly significant benefits in favour of atorvastatin over placebo on the primary coronary endpoint. All patients in ASCOT-LLA were offered open-label atorvastatin and continued in the ASCOT-BPLA until its termination after a median 5.5 years of follow-up.
Baseline characteristics of participants and primary outcomes of each arm of the trial have previously been reported. 13 -15 All events of fatal CHD, symptomatic non-fatal MI, coronary revascularization, fatal and non-fatal stroke, heart failure, renal impairment, and deaths of any cause occurring in ASCOT participants from the UK and Ireland during the study period between February 1998 and October 2005 were identified as cases. During the follow-up period of median 5.5 years, 424 CV events [255 CHD (fatal CHD, symptomatic non-fatal MI, and coronary revascularization), 114 strokes, and 55 heart failure], 104 cases of renal impairment, and 232 deaths who had valid baseline PRA blood sampling were identified. Individually matched controls were selected from the UK and Ireland ASCOT study population who were alive at the time the case was diagnosed and free from CV disease throughout the study period. Up to three controls were matched to each case by age (+1 year), sex, ethnicity, and study entry time +90 days. Forty-five cases with no matched controls were excluded from the baseline analyses. In total, 715 cases were finally matched to 1525 controls ( Figure 1 ).
Laboratory methods
Plasma renin activity was measured on samples obtained at the baseline and stored at 2808C without freeze thaw cycles, by radioimmunoassay of angiotensin 1 generated from endogenous renin substrate by the Supra-Regional Assay Laboratory at St Mary's Hospital, London, and based on the method of Menard and Catt. 16 The intra-assay coefficient of variation ranged from 7.3% at high levels to 5.0% at low levels of PRA. The corresponding inter-assay coefficients of variation were 8.8 and 8.0% respectively.
Statistical methods
Age, sex, and pre-randomized AHT drug-adjusted partial correlation coefficients were computed to evaluate the correlation between logtransformed baseline PRA and baseline clinical characteristics. The Mann-Whitney tests were used on comparison of skewed data. The first event of a composite CV endpoint (non-fatal MI, fatal CHD, coronary revascularization, fatal and non-fatal stroke, and development of heart failure) was considered in the outcome analyses. The association of baseline PRA and risk of subsequent events was reported as an odds ratio (OR) with 95% confidence intervals (CIs) obtained from a conditional logistic regression model, first by treating log-transformed baseline PRA as a continuous variable giving the odds of having an event per
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1-SD change and, secondly, by categorizing PRA into quartiles with the lowest quartile as the referent category. Conditional logistic regression models were used in order to take into account matching for sex, age, ethnicity, and study entry time. Three models were used: Model A: unadjusted; Model B: adjusted for current smoking status, diabetes mellitus, randomized atorvastatin/placebo, randomized atenolol/amlodipine, left ventricular hypertrophy, baseline systolic blood pressure, total cholesterol, HDL cholesterol, body mass index (BMI), fasting glucose, family history of CHD, creatinine, and educational attainment; Model C: same as Model B but additionally adjusting for the use of any AHT drugs 1 month prior to randomization. Plasma renin activity may be influenced by AHT drugs, particularly BBs; therefore, primary analyses (sensitivity analyses) were repeated separately on data restricted to patients who were untreated with BBs at the baseline.
All statistical tests were two-sided and a value of P , 0.05 was considered statistically significant. Analyses were performed with the use of SAS V9.1 (SAS Institute, Cary, NC, USA) and STATA V11 (STATA Corporation, College Station, TX, USA).
Results
During a median follow-up period of 5.5 years [inter-quartile range (IQR): 5.0, 6 .0], a total of 2240 cases and controls were eligible for inclusion in these analyses. Of these, 73 were excluded for missing values of baseline covariates used in the models. Table 1 summarizes the baseline characteristics of the participants according to clinical outcome. Overall, the mean age was 66.1 + 7.5 years and 82.8% were male. The majority of the participants were white European. Table 2 shows partial correlation coefficients of logged baseline PRA with clinical and biochemical characteristics adjusted for age, sex, and baseline AHT treatment. Significant positive correlations between logged baseline PRA and creatinine, total cholesterol, LDL-c, log e triglycerides, and heart rate and significant negative correlations with blood pressures were seen among cases and controls combined.
Baseline characteristics
Ninety-one per cent of the participants were on AHT treatment at the baseline. Subjects on a BB had lower median PRA (ng/mL/h) levels (1.04, IQR: 0.52, 1.3) than those not on a BB (1.69, IQR: 1.04, 3.63, P , 0.0001; Table 3 ). In contrast, subjects on an angiotensinconverting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB) had higher PRA (2.33, IQR: 1.30, 5.57) than those not on an ACEI or ARB (1.3, IQR: 0.65, 1.82, P , 0.0001). A similar higher PRA level was also seen in those on diuretics. The median level of PRA at the baseline among all participants and among those untreated at the baseline was not significantly different between those subsequently randomized to either atenolol or amlodipine (The Mann-Whitney test P ¼ 0.72 and 0.56, respectively) (data not shown).
Baseline plasma renin activity and cardiovascular events
There was no association between composite CV events and PRA as a continuous measure or categorized into quartiles in unadjusted conditional logistic models (Model A). Similarly, in multivariable-adjusted conditional logistic models (Model B; Table 4 ), baseline PRA was not associated with composite CV outcomes. The ORs for CV, CHD, stroke, and heart failure were 0.92 (95% CI: 0.81, 1.06), 0.86 (0.72, 1.03), 0.97 (0.74, 1.29), and 1.09 (0.69, 1.72) per 1-SD increase in log-transformed PRA, respectively. After additional adjustment for established CV risk factors as well as for the use of any AHT treatment 1 month prior to randomization (Model C; Table 4 and Figure 2 ), comparing with the lowest PRA quartile, the highest quartile showed a non-significant inverse association with the risk of CV, CHD, and stroke events.
Among 426 control subjects, information was available from a separate case -control study of ASCOT recruits, in which measurements of high-sensitivity C-reactive protein, cystatin C-and N-terminal pro-brain natriuretic peptide (Nt-proBNP) were also available 17 (and unpublished data). The age-and sex-adjusted correlations between log e baseline PRA and log e high-sensitivity Is PRA a biomarker for prediction of renal and CV outcomes?
C-reactive protein, log e cystatin C, and log e Nt-proBNP were 0.087 (P ¼ 0.08), 0.070 (P ¼ 0.15), and 20.22 (P , 0.0001), respectively.
Baseline plasma renin activity and renal events
Nine subjects with a CV outcome as the first event were excluded from these analyses. In Table 4 Table 4) . Analyses repeated after excluding 115 subjects who had a non-fatal CV event as their first event showed similar non-significant results.
Excluding subjects who were on b-blockers at the baseline There was no evidence of an interaction between baseline PRA and the use of BB pre-randomization on any of the study outcomes. However, primary analyses were repeated by excluding those who were taking BB at the baseline (n ¼ 986). The association between baseline PRA as a continuous variable (standardized log e PRA) and risk of CV events remained non-significant [OR 0.88 (0.69, 1.13), P ¼ 0.32]. Tertile analyses showed that the reduced risk of CV events among those in the highest tertile of PRA level remained non-significant OR 0.65 (0.36, 1.17, P ¼ 0.16) The magnitude of PRA effect on renal outcome obtained from this subgroup was greater than that from the model using all subjects but estimated ORs were not statistically significant owing to the much smaller numbers in this analysis. The PRA effect on all-cause mortality was not significantly different when analyses were confined to this subgroup ( Excluding those subjects with CV events as first event.
Discussion
The current study, in a large subgroup of hypertensive subjects randomized in the ASCOT trial, showed that PRA at the baseline was not a predictor of the subsequent development of future CV events, either MI, stroke, or heart failure. However, in models adjusted for associated baseline characteristics, there was a positive association, of borderline significance, of PRA with the subsequent development of renal impairment, which achieved statistical significance in trend analyses. While two earlier reports have suggested that treatment at the baseline does not influence the apparent association between PRA and CV events, 9, 10 in the present study, when those on BBs were eliminated, there was no significant change in the association between PRA and CV events. These refined analyses are clearly important because of the marked effects different classes of AHT drugs have on levels of PRA as shown in Table 3 .
The role of the RAAS in the pathogenesis of essential hypertension is uncertain, but there is much evidence to support its involvement, not least through the stimulation of reactive oxygen species, in causing target-organ damage. 2, 18 However, the finding that PRA predicts the development of progressive renal impairment in hypertensive patients is a new finding. Although higher levels of PRA have been reported to be associated with greater rates of chronic kidney disease, in a large population of primarily hypertensive patients, 19 and the renin precursor, prorenin, appears to predict the severity of microvascular disease, including impaired renal function, in patients with diabetes, 20 we can find no previous reports of PRA as a marker for future deterioration in renal function in hypertensive patients, although in a recently presented abstract PRA was reported to be associated with adverse renal outcomes in patients with CHD. 12 However, this new finding is entirely compatible with the knowledge that drugs which block the RAAS have, in several studies, been shown to be renoprotective. 21 In 1972, Brunner et al. 4 were the first to stimulate interest in the potential role of PRA as a predictor of future CV events in a population of 219 hypertensive patients. Measurements of PRA were related to daily sodium excretion and the PRA-sodium profiles were compared with a nomogram derived from a small number of normotensive subjects. PRA was described as being subnormal in 27% (n ¼ 59), normal in 57% (n ¼ 125), and elevated in 16% (n ¼ 35). During an average observation period of 9.7 years, there were 14 and 5 events, respectively, in those with normal or high PRA and no events in those whose PRA was subnormal.
On the basis of this small study, the authors concluded that PRA emerges as a potential risk factor for patients with essential hypertension. A further study designed to test the prognostic value of PRA, in 1717 subjects with mild-moderate hypertension, was reported by Alderman et al. 5 Again PRA-sodium profiles were obtained and subjects classified as high (12%), normal (56%), or low (32%). After an observation period of 8.3 years, during which subjects received similar AHT treatments according to a stepped-care regimen, there were 27 MIs, 7 in the high PRA group, 15 in the normal, and 5 in the low PRA group. Again the authors concluded, on the basis of these very small numbers of events, that the PRA profile before treatment was independently associated with the risk of subsequent MI. In the Northwick Park Heart Study of 803 white, male factory workers followed for an average of 13 years, during which time 86 first coronary events occurred, 6 Meade et al. reported no association between baseline PRA and coronary events [hazard ratio (HR) 1.04 (CI 0.84, 1.30) per 1-SD increase in PRA]. In the 242 men who were classified as hypertensive and in whom 44 coronary events occurred, the relative risk of those in the highest as opposed to the lowest tertile of PRA was increased, albeit non-significantly, to 1.26 (CI 0.63, 2.56). The small number of events in these early studies, particularly those conducted in hypertensive subjects, should therefore be interpreted with extreme caution. In a much larger cohort studied in the Framingham Heart Study, 7 3408 individuals (1413 hypertensive) were followed for a period of 7.1 years. Plasma renin concentration (which, prior to the advent of direct renin inhibitor therapy, has been shown to correlate well with levels of PRA 22 at the baseline was related to all-cause mortality. Plasma renin concentration did not predict CV events 23 reported that in a nested case-control study of 6105 stroke survivors, plasma renin concentration predicted subsequent MI (n ¼ 206) with an adjusted OR for subjects in the highest compared with the lowest quartile of plasma renin of 1.7 (CI 1.1, 2.8).
In the Intermountain Heart Collaborative Study 9 undertaken in 1165 patients with proven CHD followed for an average of 6. . Interestingly, in this study, associations remained significant after adjusting for treatment with drugs such as BBs and ACEIs, known to affect levels of PRA at the baseline. PRA was also significantly associated with events in the 4291 patients with chronic heart failure, recruited into the Valsartan Heart Failure Trial. 10 Baseline PRA predicted overall mortality [HR 1.12 (CI 1.06, 1.20) ] in a multivariate model and, again in this study, the baseline use of BBs or ACEIs did not affect the predictability of PRA. How then is it possible to reconcile the differences in predictability of PRA derived from these various studies? First, the early studies in hypertensive patients were very small with few coronary events, and hence, the findings are clearly not robust. Furthermore classification in some early studies was dependent on profiling PRA in relation to sodium excretion, which was not undertaken in the more recent studies. Whether this could have explained differences in outcomes can only be conjectural. Second, differences in study design-namely intervention trials, cohort studies or case -control studies may have compromised comparisons between studies. Third, differences in assay methods were apparent between studies. Small variations in the radio-immunoassay technique for measurement of PRA are unlikely to explain differences in findings between studies and comparisons of PRA with direct measurements of renin concentration in plasma have shown comparable results. 22 Fourth, the most probable explanation for the variation in results is the widely different populations under observation. There appears some consistency in the finding that PRA predicts CV events, heart failure, and all-cause death in those at high CV risk, such as those with proven coronary or other vascular disease or heart failure. 9, 10 However, in subjects at much lower risk, either unselected populations or those with uncomplicated hypertension, PRA does not appear to consistently predict future CV events.
In separate case -control studies of ASCOT participants 17 (and unpublished data), we have explored the predictability of various inflammatory, renal, and cardiac biomarkers for the future risk of CV events. We have conducted a retrospective analysis of over 400 paired samples, in which levels of PRA and the other biomarkers were available. There were no significant correlations of PRA with either CRP or cystatin-C, but there was a significant yet unexplained negative correlation with Nt-proBNP (which was strongly correlated with CV outcome).
We have previously reported risk scores for the development of resistant hypertension in a subgroup of the ASCOT patients. 24 We found no association of baseline PRA with the subsequent development of resistant hypertension. We have also recently reported 11-year mortality outcomes from ASCOT 25 and, again, found no association with baseline levels of PRA.
Limitations of the current study should be considered. First, our analyses were based on a nested case-control design, the findings of which might differ from a cohort design, although previous comparisons between case-control and cohort studies have been reported and it is reasonable to conclude that there is little loss of power with the conduct of the former compared with the latter. 26 There is a possibility that bias might occur due to more than 40% of the eligible participants being excluded from the analyses. However, the majority of non-participants were due to missing PRA values (due to inadequate blood samples) and occurred randomly among cases and controls. Secondly, due to small number of participants overlapping with a separate casecontrol study from which other biomarkers were available, we were unable to investigate any further adjustments for the PRA effect on renal events. Thirdly, the majority of patients were on treatment prior to randomization, and it is clear that different drugs had significant effects on PRA levels. We were unable to restrict all analyses to previously untreated subjects as they constituted a small minority of subjects.
In conclusion, our data have shown that elevated PRA levels in a hypertensive population with no pre-existing CV disease do not predict the future development of CV events, in contrast with the reported observations in patients with established CHD or heart failure. Our findings indicate that PRA may be a marker for the future development of renal impairment, but future observational studies and clinical trials should note the profound effects that prior AHT drugs have on PRA levels and the uncertainty with which such treatments may confound the use of PRA as a potential biomarker for CV and renal outcomes. administrative staffing and analytical costs of the biomarker analyses. M.F.P. is an employee of Novartis Pharmaceutical Co.
